Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Lytix Biopharma AS ( (DE:6BG) ).
Lytix Biopharma has completed a NOK 61 million private placement and plans a subsequent offering of up to NOK 30 million, issuing as many as 3,333,333 new shares at NOK 9.00 each to eligible existing shareholders. The planned subsequent offering, which remains subject to shareholder approval, publication of a national prospectus and market conditions, is intended to give non-participating existing investors a chance to subscribe on a pro rata basis, potentially strengthening the company’s capital base and broadening shareholder participation as it advances its oncology pipeline on Euronext Growth.
More about Lytix Biopharma AS
Lytix Biopharma AS is a clinical-stage biotech company based in Oslo, Norway, developing novel cancer immunotherapies derived from host-defense peptides. Its lead candidate, LTX-315, is a first-in-class oncolytic molecule designed to boost anti-cancer immunity, supported by a broader pipeline targeting multiple cancer indications as both mono- and combination therapies.
Average Trading Volume: 81,110
Current Market Cap: NOK678.5M
Learn more about 6BG stock on TipRanks’ Stock Analysis page.